
|Articles|March 15, 2002
InSite obtains rights to optineurin gene
A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
2
STAAR Surgical terminates proposed acquisition by Alcon
3
FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy
4
Rates of retinal layer thinning predict visual field progression in glaucoma
5












































